U.K. Spending Watchdog Rejects Avastin Again For Metastatic Colorectal Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche's offer of lump-sum payments to the NHS fails to sway NICE in its second draft evaluation of Avastin for the indication, but because it is not yet a final determination, stakeholders will have an opportunity to weigh in.
You may also be interested in...
UK Government Moves to Combat Low Uptake of Innovative Cancer Drugs
A report highlighting the low use of innovative cancer drugs in the U.K. has prompted the government to target more funding at this area. It may involve a shake-up of NICE, which the pharmaceutical industry has welcomed.
Erbitux and Avastin Aren’t Cost Effective, NICE Finds
Merck KGaA and Roche have 15 days to appeal the ruling regarding metastatic colorectal cancer.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.